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A bs tr ac t
Background
Severe hypoglycemia may increase the risk of a poor outcome in patients with type 2 
diabetes assigned to an intensive glucose-lowering intervention. We analyzed data 
from a large study of intensive glucose lowering to explore the relationship between 
severe hypoglycemia and adverse clinical outcomes.
Methods
We examined the associations between severe hypoglycemia and the risks of mac-
rovascular or microvascular events and death among 11,140 patients with type 2 dia-
betes, using Cox proportional-hazards models with adjustment for covariates mea-
sured at baseline and after randomization.
Results
During a median follow-up period of 5 years, 231 patients (2.1%) had at least one severe 
hypoglycemic episode; 150 had been assigned to intensive glucose control (2.7% of 
the 5571 patients in that group), and 81 had been assigned to standard glucose 
control (1.5% of the 5569 patients in that group). The median times from the onset 
of severe hypoglycemia to the first major macrovascular event, the first major mi-
crovascular event, and death were 1.56 years (interquartile range, 0.84 to 2.41), 0.99 
years (interquartile range, 0.40 to 2.17), and 1.05 years (interquartile range, 0.34 to 
2.41), respectively. During follow-up, severe hypoglycemia was associated with a sig-
nificant increase in the adjusted risks of major macrovascular events (hazard ratio, 
2.88; 95% confidence interval [CI], 2.01 to 4.12), major microvascular events (hazard 
ratio, 1.81; 95% CI, 1.19 to 2.74), death from a cardiovascular cause (hazard ratio, 
2.68; 95% CI, 1.72 to 4.19), and death from any cause (hazard ratio, 2.69; 95% CI, 
1.97 to 3.67) (P<0.001 for all comparisons). Similar associations were apparent for 
a range of nonvascular outcomes, including respiratory, digestive, and skin conditions 
(P<0.01 for all comparisons). No relationship was found between repeated episodes 
of severe hypoglycemia and vascular outcomes or death.
Conclusions
Severe hypoglycemia was strongly associated with increased risks of a range of ad-
verse clinical outcomes. It is possible that severe hypoglycemia contributes to adverse 
outcomes, but these analyses indicate that hypoglycemia is just as likely to be a 
marker of vulnerability to such events. (Funded by Servier and the National Health 
and Medical Research Council of Australia; ClinicalTrials.gov number, NCT00145925.)
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In patients with diabetes treated with insulin or insulin secretagogues, severe hypo-glycemia is more common when glucose con-
trol is intensified.1-4 Although most episodes of 
severe hypoglycemia resolve without apparent per-
manent injury, there are anecdotal reports of acute 
coronary syndromes coinciding with hypoglyce-
mia in people with type 2 diabetes.5,6 In addition, 
observational studies have suggested that hypo-
glycemia and reduced levels of glycated hemo-
globin are associated with an increased risk of 
death in patients with diabetes or hyperglyce-
mia who have been hospitalized for myocardial 
infarction.7-11
Recently completed trials investigating the ef-
fect of intensive glucose control on macrovascular 
outcomes in patients with long-standing type 2 
diabetes have individually failed to demonstrate 
clear reductions in cardiovascular events or mor-
tality.1-3 A meta-analysis showed that intensive 
glucose control reduced the risk of myocardial 
infarction by 15%, with no adverse effect on the 
risk of death, but that it simultaneously increased 
the risk of severe hypoglycemia.12 Nonetheless, 
the excess mortality observed with intensive glu-
cose control in the Action to Control Cardiovas-
cular Risk in Diabetes (ACCORD) study has fueled 
speculation about the adverse effects of such regi-
mens in patients with type 2 diabetes.13 Post hoc 
analyses of ACCORD study data suggest that the 
excess mortality in the intensively treated group 
was not directly explained by the high rate of hy-
poglycemia.14
We examined the relationship between severe 
hypoglycemia and the subsequent risks of vascu-
lar complications and death among 11,140 pa-
tients with type 2 diabetes who participated in the 
Action in Diabetes and Vascular Disease: Preterax 
and Diamicron Modified Release Controlled Eval-
uation (ADVANCE) study (ClinicalTrials.gov num-
ber, NCT00145925).
Me thods
Study Design and Oversight
ADVANCE was a factorial trial with two random-
ized comparisons: a double-blind assessment of 
the efficacy of perindopril–indapamide in lower-
ing blood pressure, as compared with placebo, and 
an open-label assessment of the effects of inten-
sive glucose lowering with the use of a modified-
release formulation of gliclazide as compared with 
standard, guideline-based glucose lowering on the 
risks of vascular outcomes and death among pa-
tients with type 2 diabetes. Approval for the trial 
was obtained from the ethics committee of each 
study center, and all participants provided written 
informed consent.3,15 The main results for each 
comparison have been reported previously.3,15
Study Population
A total of 11,140 patients who were at least 55 years 
of age were recruited for the study from 215 cen-
ters in 20 countries between June 2001 and March 
2003. Eligible patients had received a diagnosis of 
type 2 diabetes after the age of 30 years and had 
a history of major macrovascular or microvascu-
lar disease or at least one other cardiovascular 
risk factor.3 No threshold for level of blood glu-
cose or glycated hemoglobin was specified for in-
clusion in the study, although patients with a clear 
indication for long-term insulin use at baseline 
were ineligible. Patients assigned to the intensive 
glucose-lowering intervention were given modi-
fied-release gliclazide (Diamicron MR, Servier) and 
other glucose-lowering drugs as required, with a 
target glycated hemoglobin level of 6.5% or less.3 
Weight, height, blood pressure, and levels of gly-
cated hemoglobin and serum creatinine were mea-
sured at baseline, at 4 months, and every 6 months 
thereafter.3
Definition of Hypoglycemia
Hypoglycemia was defined as a blood glucose level 
of less than 2.8 mmol per liter (50 mg per decili-
ter) or the presence of typical symptoms and signs 
of hypoglycemia without other apparent cause. 
Patients with transient dysfunction of the central 
nervous system who were unable to treat them-
selves (requiring help from another person) were 
considered to have severe hypoglycemia. Episodes 
of severe hypoglycemia were reported at the time 
of their occurrence during study follow-up, with 
a full description of the event. Each report was 
reviewed to confirm that the criteria were met. 
Patients with transient dysfunction of the central 
nervous system who were able to treat themselves 
were considered to have minor hypoglycemia. 
Episodes of minor hypoglycemia were reported at 
follow-up visits.
Clinical Outcomes
The primary clinical outcomes considered were 
the first major macrovascular event (death from 
a cardiovascular cause, nonfatal myocardial infarc-
tion, or nonfatal stroke) and the first major micro-
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vascular event (new or worsening nephropathy or 
retinopathy). The secondary outcomes considered 
were death from any cause and death from a car-
diovascular event. Primary and secondary out-
comes were validated by an independent adjudi-
cation committee whose members were unaware 
of the treatment assignments.3 Nonvascular clin-
ical outcomes were reported during follow-up as 
serious adverse events and coded according to the 
International Classification of Diseases, 9th Revision.
Statistical Analysis
A full description of the statistical analysis is pro-
vided in the Supplementary Appendix, available 
with the full text of this article at NEJM.org. In 
brief, rates of severe and minor hypoglycemia dur-
ing follow-up were estimated for the entire cohort 
and according to treatment assignments. Baseline 
risk factors for severe hypoglycemia were exam-
ined with the use of univariate and multivariate-
adjusted Cox proportional regression models. In-
cidence rates of clinical outcomes according to 
hypoglycemic status were examined in the entire 
cohort. Crude, annualized mortality rates within 
each glucose treatment group (intensive glucose 
control and standard glucose control) for patients 
who did and those who did not report severe hypo-
glycemia were determined by dividing the num-
ber of deaths by the cumulative time at risk. 
Associations between severe hypoglycemia and 
clinical outcomes were tested with the use of time-
dependent Cox proportional-hazards models of 
the time from randomization to the first clinical 
outcome. Models were adjusted for all baseline and 
time-dependent covariates (variables measured 
during follow-up) that were thought to be poten-
tial confounders, as listed in the Supplementary 
Appendix. For each clinical outcome, the follow-
up time for every patient was divided into as many 
intervals as there were distinct event times in the 
whole cohort. Each interval included the latest 
measured value for each time-dependent covariate 
and a variable indicating whether the patient had 
the clinical outcome of interest during that inter-
val.16 Follow-up for each participant was consid-
ered separately for each major outcome and ended 
on the date of the first clinical event, the date 
of death, or the date of data censoring at study 
completion. 
The primary analysis assumed that patients 
were exposed to hypoglycemia from the time of 
the first severe hypoglycemic episode until the end 
of follow-up or the occurrence of a clinical event. 
Additional sensitivity analyses tested various expo-
sure times, use of logistic-regression models, and 
additional adjustment for cardiovascular events 
occurring after randomization, as described in the 
Supplementary Appendix. Model predictive capac-
ity, with and without severe hypoglycemia, was 
tested with the use of C statistics,17 the integrated-
discrimination-improvement statistic,18 and the 
Hosmer–Lemeshow chi-square statistic.19 Analy-
ses were performed with the use of SAS statisti-
cal software, version 9.1 (SAS Institute). All statis-
tical tests were two-sided, and a P value of less 
than 0.05 was considered to indicate statistical 
significance, but all results were interpreted in 
light of the many comparisons made.
R esult s
Rates of Hypoglycemia over Time
During a median follow-up period of 5 years, 231 
of 11,140 study patients (2.1%) reported 299 se-
vere hypoglycemic events: 150 patients in the in-
tensive-intervention group (2.7%) reported 195 
events, and 81 patients in the standard-interven-
tion group (1.5%) reported 104 events (Table 1). 
Over time, the rate of severe hypoglycemia in-
creased in the group undergoing intensive glucose 
control (P<0.001 for trend) but remained relatively 
stable in the group receiving standard treatment 
(P = 0.38 for trend) (Fig. 1A). A total of 4975 pa-
tients (44.7%) reported minor hypoglycemia dur-
ing follow-up; 2898 of these patients (52.0%) had 
been assigned to intensive control and 2077 (37.3%) 
to standard control (Table 1).
Risk Factors for Severe Hypoglycemia
Univariate and multivariate analyses showed that 
the following variables were independent risk fac-
tors for severe hypoglycemia: older age, longer du-
ration of diabetes, higher creatinine levels, lower 
body-mass index, lower cognitive function, use of 
two or more oral glucose-lowering drugs, history 
of smoking or microvascular disease, and assign-
ment to intensive glucose control (P<0.05 for all 
comparisons; for details, see Table 1 in the Sup-
plementary Appendix). When these analyses were 
stratified according to treatment group, the risk 
factors for severe hypoglycemia were similar.
Association of Severe Hypoglycemia  
with Vascular Outcomes and Death
During follow-up, 2125 patients had a major mac-
rovascular or microvascular event, 87 of whom re-
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ported severe hypoglycemia (before the event in 
40 patients and after the event in 47), and 1031 
patients died, 45 of whom had reported severe hy-
poglycemia. The median times from the episode 
of severe hypoglycemia to the subsequent first 
major macrovascular or microvascular event were 
1.56 years (interquartile range, 0.84 to 2.41) and 
0.99 years (interquartile range, 0.40 to 2.17), re-
spectively. The median time from severe hypogly-
cemia to death was 1.05 years (interquartile range, 
0.34 to 2.41) — 1.31 years (interquartile range, 
0.80 to 2.41) for death from a cardiovascular event 
and 0.74 years (interquartile range, 0.13 to 2.60) for 
death from a noncardiovascular cause (Fig. 1B).
Among patients who reported severe hypogly-
cemia, 16.8% (35 of 208) had a subsequent major 
macrovascular event, 11.5% (24 of 209) had a sub-
sequent major microvascular event, and 19.5% (45 
of 231) died; the respective rates for those who 
did not report severe hypoglycemia were 10.2% 
(1112 of 10,932 patients), 10.1% (1107 of 10,931), 
and 9.0% (986 of 10,909), respectively. The propor-
tions of patients who died from cardiovascular 
causes and from noncardiovascular causes were 
similar among patients reporting severe hypogly-
cemia (49% and 51%, respectively) and those not 
reporting severe hypoglycemia (53% and 47%, re-
spectively; P = 0.09). For those reporting severe hy-
poglycemia, annual death rates were lower in the 
group receiving intensive treatment than in the 
group receiving standard treatment (3.6% vs. 5.1%). 
In contrast, for those not reporting severe hypo-
glycemia, annual death rates were similar in the 
two treatment groups (1.8% with the intensive 
intervention and 1.9% with standard treatment) 
(Table 2). There was no evidence of interaction 
among severe hypoglycemia, the assigned glucose-
lowering treatment, and the risk of death (P = 0.30).
The unadjusted risks of a major macrovascular 
event, a major microvascular event, death from any 
cause, and death from a cardiovascular or non-
cardiovascular cause were significantly increased 
among patients who had severe hypoglycemia as 
compared with those who did not (Table 3). After 
adjustment for a number of potential confound-
ing variables measured at baseline or during fol-
low-up, the associations were markedly attenuated 
but remained significant (P<0.01 for all com-
parisons).
In analyses in which the period of follow-up 
after a severe hypoglycemic episode was limited 
to 3 months and to 6 months, the unadjusted and 
adjusted associations with all major macrovascu-
lar outcomes and death (from any cause or from 
a cardiovascular or noncardiovascular cause), re-
mained significant (Table 3). The adjusted asso-
ciations for major microvascular events were no 
longer significant when the period was limited to 
3 months, but the point estimates of association 
were similar (Table 3). When the analyses were 
Table 1. Episodes of Severe and Minor Hypoglycemia in All Study Participants and According to Treatment Group.
Variable
All Participants 
(N = 11,140)
Intensive 
Glucose 
Control 
(N = 5571)
Standard 
Glucose 
Control 
(N = 5569)
Hazard Ratio 
(95% CI)
Severe hypoglycemia 1.86 (1.40–2.40)
No. of patients (%) 231 (2.1) 150 (2.7) 81 (1.5 )
No. of episodes
One 184 120 64
Two 35 22 13
Three or more 12 8 4
Rate (per person per year) 0.006 0.007 0.004
Minor hypoglycemia 1.58 (1.49–1.68)
No. of patients (%) 4975 (44.7) 2898 (52.0) 2077 (37.3)
No. of episodes
One 2610 1529 1081
Two 671 397 274
Three or more 1694 972 722
Rate (per person per year) 1.1 1.2 0.9
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stratified according to treatment group, the find-
ings were consistent in the two groups (P>0.10 
for all interactions). The observed associations 
were also similar among patients with and those 
without a history of macrovascular disease at study 
entry (P>0.10 for all interactions).
There was no evidence of a dose–response re-
lationship between repeated episodes of severe 
hypoglycemia and vascular outcomes or death, 
although few patients had recurrent events (for 
details, see Table 2 in the Supplementary Appen-
dix). For example, the adjusted odds ratio for death 
from any cause was 1.57 (95% confidence interval 
[CI], 1.02 to 2.41) with a single severe hypoglyce-
mic episode and 1.24 (95% CI, 0.58 to 2.68) with 
two or more episodes (P>0.10 for the comparison 
of risk among those reporting two or more hypo-
glycemic episodes vs. those reporting one episode). 
When we examined the effect of adding the oc-
currence of severe hypoglycemia to models pre-
dicting absolute risks of vascular outcomes and 
death, we found no improvement in prediction for 
any outcome (P≥0.05 for all C statistics; for details, 
see Table 3 in the Supplementary Appendix).
Association of Minor Hypoglycemia  
with Vascular Outcomes and Death
The risks of major macrovascular outcomes and 
death were reduced among patients reporting mi-
nor hypoglycemia as compared with those who did 
not report minor hypoglycemia (for details, see 
Table 4 in the Supplementary Appendix). Howev-
er, there was an increased risk of major microvas-
cular events (unadjusted odds ratio, 1.25; 95% CI, 
1.11 to 1.42; P<0.001; adjusted odds ratio, 1.29; 
95% CI, 1.13 to 1.48; P<0.001).
Association of Severe Hypoglycemia  
with Nonvascular Outcomes
During follow-up, disorders of the respiratory sys-
tem, the digestive system, and the skin developed 
in some study participants, as did cancer (Fig. 2). 
The unadjusted risks of these nonvascular condi-
tions were increased among patients who report-
ed severe hypoglycemia as compared with those 
who did not (Fig. 2). After adjustment, the asso-
ciations remained significant for all outcomes ex-
cept cancer (P<0.05 for all comparisons) (Fig. 2).
Additional Sensitivity Analyses
The observed associations between severe hypo-
glycemia and the risks of major vascular events and 
death were robust on examination with pooled 
logistic regression. For the risk of death from any 
cause, further adjustment for cardiovascular events 
occurring after randomization resulted in addi-
tional attenuation of the odds ratio, from 2.61 (95% 
CI, 1.74 to 3.93) to 1.34 (95% CI, 0.79 to 2.27).
Discussion
In the ADVANCE study, severe hypoglycemia was 
clearly associated with increased risks of macro-
vascular events, microvascular events, and death 
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Figure 1. Annual Rates of Severe Hypoglycemia According to Treatment 
Assignment and Adverse Clinical Outcomes among Patients with Severe 
Hypoglycemia.
Panel A shows the rates of severe hypoglycemia in the group assigned to 
the intensive glucose­lowering intervention (P<0.001 for trend) and the 
group assigned to standard glucose control (P = 0.38 for trend). Panel B 
shows the frequency of adverse clinical outcomes after the occurrence of a 
severe hypoglycemic episode.
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from both cardiovascular and noncardiovascular 
causes. Risks were also increased for a range of 
nonvascular events that included cancer and con-
ditions affecting the respiratory system, the diges-
tive system, and the skin. The association of hy-
poglycemia with increased risks of vascular events, 
nonvascular events, and death were similar for pa-
tients assigned to standard glucose control and 
those assigned to intensive glucose control, and 
although it was attenuated after adjustment for 
potential confounding factors, the association re-
mained significant for most outcomes. These 
findings in a community-dwelling population of 
patients reporting severe hypoglycemia are sup-
ported by other data,8-11,20,21 including a recent 
report from the ACCORD study group.14
Plausible mechanisms by which hypoglycemia 
might cause cardiovascular disease or lead to 
death from cardiovascular disease include sympa-
thoadrenal activation, abnormal cardiac repolar-
ization, increased thrombogenesis, inflammation, 
and vasoconstriction.22 In a recent study involving 
healthy volunteers, two induced episodes of mild 
hypoglycemia led to impaired cardiac autonomic 
function the day after each episode.23 Although it 
is unclear whether such effects persist, impaired 
cardiac autonomic function is associated with in-
creased mortality among patients at high cardio-
vascular risk,24-26 including those with diabetes.27 
We did not measure autonomic function and 
therefore could not examine its contributory ef-
fects. It is possible that episodes of asymptomatic 
or unreported symptomatic hypoglycemia fol-
lowed the initial occurrence of severe hypoglyce-
mia and thus contributed to the increased risk of 
subsequent events. Patients who have repeated 
hypoglycemic episodes often have decreased aware-
ness of hypoglycemia,28 and lack of awareness 
might explain the absence of any clear temporal 
link between severe hypoglycemia and the adverse 
outcomes observed in our analyses.
It is also possible that severe hypoglycemia re-
flects the effects of coexisting conditions and un-
measured or incompletely quantified confound-
ing variables and is a marker of an increased risk 
of adverse clinical outcomes rather than a direct 
cause.29 The marked attenuation of the risk esti-
mates after adjustment for a number of baseline 
and time-dependent characteristics of the patients 
suggests that the effects of confounding were sub-
stantial. The presence of coexisting conditions 
could increase a patient’s vulnerability to both se-
vere hypoglycemia and an adverse clinical outcome 
in the absence of a direct causal link between the 
two. For example, the observed association be-
tween severe hypoglycemia and microvascular 
disease may be more easily explained by the pres-
ence of risk factors common to both (e.g., older 
age and longer duration of diabetes) than by a di-
rect effect of hypoglycemia on the occurrence of 
nephropathy or retinopathy. In addition, the short-
er interval between a reported episode of severe 
hypoglycemia and death than between such an 
episode and a macrovascular event suggests that 
among patients with severe hypoglycemia, those 
who died were sicker at the time of their episode 
of hypoglycemia than those who had other types 
of events.
In both the ADVANCE study and the ACCORD 
study,14 annual mortality among patients who 
reported severe hypoglycemia was higher in 
the group receiving standard treatment than in 
the group receiving intensive treatment. Despite 
the higher rate of severe hypoglycemia in the lat-
ter group, hypoglycemia was not considered to be 
a likely explanation for the excess mortality associ-
ated with intensive control in the ACCORD trial. 
In the ADVANCE study, intensive glucose control 
was not associated with excess mortality. In con-
junction with the absence of a clear dose–response 
relationship between repeated episodes of hypo-
glycemia and subsequent macrovascular events or 
Table 2. Unadjusted, Annualized Mortality Rates and Hazard Ratios According to Treatment Group and Status 
with Respect to Severe Hypoglycemia.
Severe Hypoglycemia Deaths (N = 1031)
Unadjusted 
Hazard Ratio (95% CI)
Intensive Glucose Control Standard Glucose Control
no. of deaths/no. of person-yr (% per yr)
No episodes   472/26,034 (1.8)   514/26,392 (1.9) 0.93 (0.82–1.06)
One or more episodes 26/718 (3.6) 19/369 (5.1) 0.67 (0.37–1.21)
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death, these observations add to the uncertainty 
about the direct causal relationship between hy-
poglycemia and death and between hypoglycemia 
and vascular outcomes.
Our study is among the largest to examine 
the association of severe hypoglycemia with mac-
rovascular and microvascular events and death 
from cardiovascular and noncardiovascular causes. 
The substantial size of the cohort and the rela-
tively large numbers of events recorded allowed 
us to examine associations with temporal and 
statistical precision. Severe hypoglycemic events 
and clinical outcomes were systematically reported 
as serious adverse events and were subject to 
rigorous independent review. However, the num-
ber of patients reporting severe hypoglycemia 
was relatively small. In addition, the occurrence 
of severe hypoglycemia before study entry and 
the presence of autonomic neuropathy were not 
recorded. Episodes of hypoglycemia that may have 
contributed to adverse outcomes but that did not 
meet the definition of severe hypoglycemia may 
have been unreported. In addition, patients and 
their care providers may have been unaware of 
minor hypoglycemic episodes. Given these con-
siderations, the reliability of the measurement of 
the total hypoglycemic burden remains somewhat 
uncertain.
In conclusion, our study shows that severe hy-
poglycemia is strongly associated with increased 
risks of a broad range of adverse clinical outcomes 
in patients with long-standing type 2 diabetes, 
including vascular events and death. Neither a 
close temporal relationship nor a dose–response 
relationship was observed. Although our findings 
cannot exclude the possibility that severe hypo-
glycemia has a direct causal link with these out-
comes, they suggest that it is as likely to be a 
marker of vulnerability to a wide range of adverse 
clinical outcomes. In either case, the presence of 
Table 3. Hazard Ratios for Incident Vascular Outcomes and Death among Patients Who Had Severe Hypoglycemia as Compared with Those 
Who Did Not.*
Clinical Outcome and Interval 
after Hypoglycemia No. of Events
Hazard Ratio 
Adjusted for
Treatment Assignment 
(95% CI) P Value
Hazard Ratio 
Adjusted for
Multiple Covariates 
(95% CI)† P Value
Macrovascular events 1147 4.05 (2.86–5.74) <0.001 3.45 (2.34–5.08) <0.001
3 mo 3.27 (1.22–8.73) 0.02 3.55 (1.32–9.54) 0.01
6 mo 2.61 (1.17–5.83) 0.02 2.75 (1.22–6.19) 0.01
Microvascular events 1131 2.39 (1.60–3.59) <0.001 2.07 (1.32–3.26) <0.001
3 mo 2.90 (1.09–7.74) 0.03 1.96 (0.63–6.17) 0.24
6 mo 3.24 (1.62–6.50) <0.001 2.41 (1.07–5.43) 0.03
Death from any cause 1031 4.86 (3.60–6.57) <0.001 3.30 (2.31–4.72) <0.001
3 mo 10.4 (6.02–18.00) <0.001 5.86 (2.97–11.60) <0.001
6 mo 7.28 (4.50–11.80) <0.001 4.28 (2.36–7.75) <0.001
Death from cardiovascular cause 542 4.87 (3.17–7.49) <0.001 3.78 (2.34–6.11) <0.001
3 mo 6.25 (2.34–6.70) <0.001 5.35 (1.94–14.80) <0.01
6 mo 4.20 (1.74–10.10) <0.01 3.57 (1.43–8.90) 0.01
Death from noncardiovascular cause 489 4.82 (3.16–7.35) <0.001 2.86 (1.67–4.90) <0.001
3 mo 14.20 (7.35–27.60) <0.001 6.19 (2.47–15.50) <0.001
6 mo 10.30 (5.78–18.20) <0.001 4.95 (2.26–10.80) <0.001
* Severe hypoglycemia was defined as a blood glucose level of less than 2.8 mmol per liter (<50 mg per deciliter), with transient dysfunction 
of the central nervous system, without other apparent cause, during which the patient was unable to administer treatment (requiring help 
from another person).
† Covariates included sex, duration of diabetes, treatment assignment, presence or absence of a history of macrovascular disease, presence 
or absence of a history of microvascular disease, and smoking status at baseline. Time­dependent covariates during follow­up included age; 
level of glycated hemoglobin; body­mass index; creatinine level; ratio of urinary albumin to creatinine; systolic blood pressure; use or non­
use of sulfonylurea, metformin, thiazolidinedione, insulin, or any other diabetes drug; and use or nonuse of antihypertensive agents.
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severe hypoglycemia should raise clinical suspi-
cion of the patient’s susceptibility to adverse out-
comes and prompt action to address this possi-
bility.
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Figure 2. Association of Severe Hypoglycemia with the Risk of an Adverse Clinical Outcome or Death.
The hazard ratio represents the risk of an adverse clinical outcome or death among patients reporting severe hypo­
glycemia as compared with those not reporting severe hypoglycemia. The centers of the squares are placed at the 
point estimates, and the horizontal lines represent the corresponding 95% confidence intervals. The area of each 
square is proportional to the inverse of the variance of each estimate. The estimates were adjusted for the baseline 
covariates of age, sex, treatment assignment, duration of diabetes, presence or absence of a history of macrovascu­
lar disease, presence or absence of a history of microvascular disease, and smoking status and for the time­depen­
dent covariates of the use of sulfonylurea, metformin, thiazolidinedione, insulin, and any diabetes drug and the use 
of antihypertensive therapy; glycated hemoglobin; body­mass index; creatinine level; ratio of urinary albumin to cre­
atinine; and systolic blood pressure.
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